Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

- 162,189 -

Net loss $(9,051,670) $(13,770,095) $(42,249,366) $(41,990,154)

Basic and diluted

net loss per share $(0.19) $(0.44) $(0.96) $(1.38)

Shares used in

calculation of

basic and diluted

net loss per share 46,734,506 31,503,384 43,816,145 30,535,965

MIDDLEBROOK PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

December 31,

2007 2006

ASSETS

Current assets:

Cash and cash equivalents $1,951,715 $14,856,738

Marketable securities - 522,723

Accounts receivable, net 687,787 303,514

Inventories, net 687,933 2,077,390

Prepaid expenses and other

current assets 1,142,905 1,682,685

Total current assets 4,470,340 19,443,050

Property and equipment, net 10,928,659 11,764,627

Restricted cash 872,180 872,180

Deposits and other assets 174,965 1,548,585

Intangible assets, net 7,219,651 8,377,327

Total assets $23,665,795 $42,005,769

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:

Accounts payable $1,659,752 $2,285,736

Accrued expenses and advances 5,613,544 7,817,224

Lines of credit and short term debt - 6,888,889
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)... 6 Calbiotech, Inc. announced toda...tive Research (SBIR) Phase I contract by the U.S. ...terms of the agreement, Calbiotech will develop an...f Dengue virus. ,, Dengue virus is a mosquit...o military forces deployed to tropical areas of th...
(Date:11/6/2009)...nda for Arrowhead’s 2010 Personalized Medici...lace on February 22-24, 2010 in Philadelphia, has ...ll highlight key issues in forming partnerships an...ces. , Minneapolis, MN (P...’s 2010 Personalized Medicine Partnerships ...
(Date:11/5/2009)...PRNewswire/ -- The endangered black-footed ferrets...is rare carnivore feeds on prairie dogs. The pra... entire population die-offs in towns occur. The U...ted a ferret breeding program and has been releasi...tive habitat. Unfortunately, plague can sweep thr...
(Date:11/5/2009).... 5 ThermoGenesis Corp. ... products for processing and storing adult stem ce...of fiscal 2010. ,, For the quarter ended Septem...2 million, a 15 percent increase over revenues of ...Company said the key contributors to the growth in...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Colorado Companies Team Up With U.S. Fish & Wildlife Service to Protect Black-Footed Ferret 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8
...ioness Inc., an innovative provider of advanced ne...very from central nervous system disorders, announ...’s largest provider of inpatient rehabilitat...ity of the NESS H200 Hand Rehabilitation System an...bilitation hospitals nationwide. , ...
...RUG DEVELOPMENT, ROCKVILLE, Md., July 30 Stem ce...d that Dr. Thomas Hazel will be,rejoining the comp... be,working with Dr. Karl Johe, Neuralstem,s Chair...ny,s upcoming clinical trial for ALS,(Amytrophic L...mplete,development of Neuralstem,s small molecule ...
... Development Of Lead Drug Candidates, MARKHAM, ON...d the,closing of a CDN $45 million Series C financ...ubishi Tanabe Pharma Corporation ("MTPC"), and sup... Vengrowth Advanced Life,Sciences Fund Inc., Caiss...an Medical Discoveries Fund Inc., T(2)C(2)/Bio 200...
Other Biology Technology: Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 2 Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide 3Neuralstem Fills Key Product Development Position 2Cytochroma Closes $45 Million Series C Financing 2Cytochroma Closes $45 Million Series C Financing 3
(Date:11/8/2009)...ers at Purdue University have discovered a new app... cord injuries using nano-spheres that could be in..., The synthetic "copolymer micelles" are drug-del...roughly 100 times smaller than the diameter of a r...how to deliver drugs for cancer treatment and othe...
(Date:11/6/2009)...in harmony with their arboreal hosts. But new rese...heir trees of choice, the ants can get destructive... in the November issue of the American Naturalist...ve trees, and it reopens a centuries-old debate on...s and certain species of plants and trees have coz...
(Date:11/5/2009)...rded a training grant in the amount of $2,756,719 ...rative Graduation Education and Research Training ...be awarded to Kent State. The grant, which is fund...t of 2009, runs through 2014. , The grant funds ...ic resource sensing (EARS). The purpose of the pro...
Breaking Biology News(10 mins):Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Ants are friendly to some trees, but not others 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 1Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 2Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 3Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 4Frost 26 Sullivan Recognizes Cisbio Bioassays for Technology Innovation 12546 5Alcohol advertising self regulation not working as ads target younger drinkers 48311 1Alcohol advertising self regulation not working as ads target younger drinkers 48311 2Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 1Researchers estimate risk of transmission of Huntingtons disease to offspring among male carriers 48309 2
...the results are receiving rave reviews from apple ...nd research, a new apple cultivar has been introdu...ing program of the Illinois, New Jersey, and India...apple will be sold under the name ,WineCrisp,. Sch...urces and Environmental Sciences at the University...
...produce, which includes packaged lettuces, has gre...tbreaks associated with these products. To reduce ...s are used for decontamination once the food is ha...e fields is equally important. Researchers from th...f California, Davis and University of Arizona), le...
...tigators have uncovered a mechanism that helps exp...lar mood disorder, also protects the brain from da...n the May 1 issue of the Journal of Clinical Inve...how that lithium promotes DNA repair in healthy ce...gest that lithium treatment could offer a way to p...
Other Biology News:Apple enthusiasts welcome WineCrisp 2Protecting fresh-cut produce 2Lithium may help radiation target cancer, spare healthy tissue 2Lithium may help radiation target cancer, spare healthy tissue 3
...nity Life Sciences can provide custom microplate c...croplate processing equipment that dispenses and w...mmodate virtually any lot size of the following fo... 8 and 12 well strips, 96 well microplate, ...
Cytomics FC 500 Series Flow Cytometry Systems from Beckman Coulter
Mynox Mycoplasma Elimination Reagent from Minerva Biolabs GmbH
Mynox Mycoplasma Elimination Reagent from Sigma-Aldrich
Biology Products: